My portfolio as of 06/21/2012:
1. ALIM
EXECUTION
![]() |
| 9-month |
Event1: I found ALIM in the list of "Unusual volume" on Finviz. A substantial drop a month ago followed by a volume increase without major news suggest someone knew something. <<<I day-traded ALIM because 1. Big loser has to bounce back a bit. (oversold) 2. Volume up with no news. It should have another bounce when news comes out. Even if I got trapped today, I would still have chance to get out when news comes out.>>>
Event2: After 2 months, I set a limit sell order at 2.1 and it was filled when the price increased by 30% one day without news. <<<I closed the position early because it was still in the "rumor" stage. However, it did reduce the risk because my position in ALIM was too high. >>>
EventX: Right after I sold 20%, major news came out that the drug won approval in Europe. I did not sell. <<<Greed took over. I convinced myself I would hold ALIM for the long run. "Buy the rumor, sell the news" is never wrong. Because of the substantial price jump, it has to pull back. Even if I wanted to "invest" in this stock, it was high time I closed the position and waited for a pull back to jump back in.>>>
ANALYSIS
![]() |
| 10-week |
It sees a spike every time approval news comes out. First approval was the most significant. Approvals are coming in the following countries: France, Germany, Italy and Spain. The stock is due for a spike based on new approvals.
![]() |
| 10-day |
PLAN
Short term: Add 25% at 2.60±0.03 level or even higher between 06/22-06/27. Company expects to meet FDA this coming week. Depend on the news, exit 30% at 2.95-3.00 level.
Long term: Company awaits good news from EU for approvals and possibly partnership. Possible resolution with FDA. Risk: Dilution of shares by raising capital. This should not come soon.
LESSON LEARNED
Buy the rumor, sell the news.
2. PBIO
EXECUTION
![]() |
| 12-month |
E4-6: All three positions were established when the stock was oversold. I almost always bought in at the low of the day. However, I failed again to exit when I had many chances.
ANALYSIS
The price hit 52-week low today at $0.20, but I still have trust in this company. Especially the CEO bought in at $0.8 level. Also the partnership with small companies since April was very positive. These small companies are the "big" names in proteomics sample prep area. The price decline may be due to a lack of interest plus MM manipulation. There is also worry of the debt and stock dilution as the company needs to raise capital for expansion. I think today or tomorrow may be the critical point for a leg up. (hitting low at low volume)
PLAN
PBIO is way oversold at this level. I'm expecting PBIO to gradually ease back to $0.40 level. Considering the risk of a low-float stock and my heavy position, I am not buying more at this level. I will just hold and watch. Plan to sell 33% at $0.60 level.
LESSON LEARNED
Before taking any position, plan the exit and stick to it. Greedy pigs get slaughtered.
3. THQI
EXECUTION
![]() |
| 7-month |
ANALYSIS
All gaming companies are not doing well. Pro: This company could be bought out. Sit tight long enough, I believe it will turn around. Con: Cash is very low. Lawsuits are against them. Management seems to be dishonest.
PLAN
Exit position at 0.75-0.8 level. I should have cut loss a month earlier.
LESSON LEARNED
Don't buy without homework. Know when to exit a losing trade.
4. DYN
EXECUTION
![]() |
| 8-month |
ANALYSIS
It is a bankrupted company with fraudulent behavior. That says enough about its credibility. It probably won't turn around for years.
PLAN
Hold till slightly below $1 to cut loss since not much value is left.
LESSON LEARNED
Greedy pigs get slaughtered. When reaching a must-cut-loss point, CUT LOSS right away.
5. AMBS
EXECUTION
![]() |
| 11-month |
ANALYSIS
Penny stock is risky. Need to be quick. I had chance to exit my position but I didn't. Greed!
PLAN
Hold on to it and hope some day it comes popping.
LESSON LEARNED
Penny stock either not to touch or get in and get out quick.









No comments:
Post a Comment